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We recently derived pluripotent stem cells with an expanded potency for both 44 
extraembryonic and embryonic cell lineages (EPSCs) from individual blastomeres by 45 
inhibiting the activity of critical molecular pathways that predisposes lineage 46 
differentiation in the mouse preimplantation embryo [1]. We now report the 47 
derivation of porcine EPSC (pEPSC) lines either directly from preimplantation 48 
embryos or by reprogramming fetal fibroblasts. The pEPSCs express key pluripotency 49 
genes, contribute to both trophoblast and embryonic tissues in the chimeras, and 50 
produce primordial germ cell-like cells (PGCLCs) in vitro. Under similar culture 51 
conditions, human ESCs and iPSCs can be converted or somatic cells directly 52 
reprogrammed to EPSCs (hEPSCs) that display the molecular and functional 53 
attributes reminiscent of pEPSCs and human 8-cell and morula stage embryos. 54 
Significantly, trophoblast stem cells can be generated from both human and porcine 55 
EPSCs. Our pathway-inhibition paradigm opens a new avenue for isolating EPSCs in 56 
mammalian species in which pluripotent embryonic stem cells are yet to be 57 
established. These stem cells, which are proximal to the totipotency state, present new 58 
opportunities for translational research in biotechnology and regenerative medicine.   59 
 60 
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To this date, bona fide pluripotent stem cells have yet to be established from 67 
preimplantation porcine embryos [2-9]. We have recently demonstrated that by 68 
targeting key molecular pathways that drive lineage differentiation in the 69 
preimplantation embryo, mouse expanded potential stem cells (mEPSCs) displaying a 70 
broad propensity for extraembryonic and embryonic lineage differentiation can 71 
successfully be derived [1].  We hypothesized that a similar experimental paradigm of 72 
targeting key developmental pathways could be applied for establishing pluripotent 73 
stem cell lines from porcine preimplantation embryos. Since little is known about the 74 
molecular and signalling mechanisms of porcine early preimplantation embryo 75 
development, we elected to perform a chemical screen of inhibitors that were used for 76 
isolating and maintaining mouse ESCs, mEPSCs and human ESCs to delineate the 77 
optimal condition for pig pluripotent stem cells. While porcine iPSCs are available, 78 
the use of these cells for the screen is confounded by the leaky expression of 79 
transgenic reprogramming factors after reprogramming or low levels of expression of 80 
endogenous pluripotency genes [10-18]. To overcome this challenge, we generated 81 
new porcine iPSCs that expressed Doxycycline (Dox)-inducible LIN28, NANOG, 82 
LRH1 and RARG, in concert with the four Yamanaka factors. This strategy 83 
substantially improved the efficiency of reprogramming wild-type German Landrace 84 
porcine fetal fibroblasts (PFFs) and transgenic PFFs, in which a tdTomato cassette 85 
had been inserted into the 3’ UTR of the porcine OCT4 (POU5F1) locus (POT PFFs) 86 
[19], to putative iPSC colonies (Extended Data Fig. 1a-c). The reprogrammed primary 87 
colonies from POT PFFs were OCT4-tdTomato+, indicating the re-activation of the 88 
OCT4 locus (Extended Data Fig. 1c). Indeed, the iPSCs expressed high levels of the 89 
endogenous pluripotency factors revealed by RT-qPCR (Extended Data Fig. 1d), and 90 
could be passaged as single cells for more than 20 passages in serum-containing 91 
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medium (M15) plus Dox. Upon Dox removal, the iPSCs differentiated within 4-5 92 
days, concomitant with the rapid down-regulation of the exogenous reprogramming 93 
factors and endogenous pluripotency genes and with the increased expression of both 94 
embryonic and extraembryonic cell lineage genes (Extended Data Fig. 1e-h). These 95 
Dox-dependent porcine iPSCs with robust endogenous pluripotency gene expression 96 
provided the material for the chemical screen.   97 
In the screen, over 400 combinations of 20 small molecule inhibitors and cytokines 98 
were tested in their ability to maintain Dox-independent pig iPSCs in the 99 
undifferentiated state (Extended Data Fig. 2a; Supplementary Table 1). A departure 100 
was noted from previous reports that naïve mouse ESC medium 2i/LIF was able to 101 
maintain putative pig iPSCs [14, 16, 20]: pig iPSCs were rapidly lost in the presence 102 
of Mek1 inhibitor PD-0325901, irrespective of whether Dox was present or not  103 
(Extended Data Fig. 2b-h), indicating that a certain level of Mek-ERK signalling 104 
would be vital for pig pluripotent stem cells. Inhibition of p38 and PKC was also non-105 
conducive for pig iPSCs (Extended Data Fig. 2b-h and Extended Data Fig. 3a). These 106 
findings led us to conclude that mouse or human naïve ESC conditions [21-23] cannot 107 
be directly extrapolated to pig pluripotent stem cells, and these three inhibitors were 108 
therefore excluded from the screen. Our work identified several conditions (Extended 109 
Data Fig. 2h), including a minimal requisite condition (#517, pig EPSC medium: 110 
pEPSCM) comprising inhibitors for GSK3 (CHIR99021), SRC (WH-4-023) and 111 
Tankyrases (XAV939) (the last two were inhibitors important for mouse EPSCs[1]), 112 
and supplements: Vitamin C (Vc), ACTIVIN A and LIF (Extended Data Fig. 2a, 2h 113 
and Supplementary Table 1). Under this condition, the Dox-independent iPSCs 114 
(pEPSCiPS) remained undifferentiated in 30 passages, expressed endogenous 115 
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pluripotency factors at levels comparable to the porcine blastocyst and showed no 116 
leaky expression of the exogenous reprogramming factors (Extended Data Fig. 3b-d).  117 
We next repeated the PFF reprogramming experiment by directly culturing the 118 
primary colonies in pEPSCM (Extended Data Fig. 3e), and generated 11 stable 119 
pEPSCiPS lines from 16 primary colonies (70% efficiency).  All lines expressed high 120 
levels of endogenous pluripotency genes and six of them did not have detectable 121 
expression of any of the eight exogenous reprogramming factors (Extended Data Fig. 122 
3f). We next employed this pEPSCM condition to derive stem cell lines directly from 123 
pig preimplantation embryos. A total of 26 lines (pEPSCsEmb, 14 male and 12 female) 124 
were established from 76 early blastocysts (5.0 dpc), and 12 cell lines (pEPSCspar) 125 
from 252 parthenogenetic blastocysts (Fig. 1a, Table 1 and Extended Data Fig. 3g). 126 
Like the pEPSCsiPS, pEPSCsEmb had high nuclear/cytoplasmic ratios, formed compact 127 
colonies with smooth colony edges (Fig. 1a, Extended Data Fig. 3h).  The pEPSCsEmb 128 
were passaged every 3-4 days at 1:10 ratio as single cells and could be maintained for 129 
>40 passages without overt differentiation. Subcloning efficiency was about 10% at 130 
low cell density (2,000 cells per well in 6-well plate), but high cell densities were 131 
always used in routine passaging. pEPSCsEmb were karyotypically normal after 25 132 
passages (Extended Data Fig. 4a).  133 
The pEPSCsEmb and pEPSCiPS expressed pluripotency genes at comparable levels as 134 
the blastocysts (Extended Data Fig. 3f), which were verified by immunostaining 135 
(Extended Data Fig. 4b). They showed extensive DNA demethylation at the OCT4 136 
and NANOG promoter regions (Fig. 1b), had OCT4 distal enhancer activity (Extended 137 
Data Fig. 4c).  The EPSCs were amenable for Crispr/Cas9-mediated insertion of a 138 
H2B-mCherry expression cassette into the ROSA26 locus (Extended Data Fig. 4d and 139 
4e). In vitro, pEPSCs differentiated to tissues expressing the markers of three germ 140 
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layers: SOX7, AFP, T, DES, CRABP2, SMA, β-Tubulin and PAX6 and, uniquely, 141 
the trophoblast markers HAND1, GATA3, PGF and KRT7 (Fig. 1c, Extended Data 142 
Fig. 4f). In immunocompromised mice, pEPSCsEmb formed mature teratomas 143 
containing derivatives of the three germ layers and placental lactogen-1 positive (PL-144 
1+) trophoblast-like cells (Fig. 1d and 1e). These results indicate that pEPSCsEmb and 145 
pEPSCsiPS, like mEPSCs [1], may possess an expanded differentiation potential for 146 
both the embryonic and extra-embryonic trophoblast lineages. The pEPSCs were 147 
tested for their contribution to blastocyst cell lineages in chimeras. Following 148 
incorporation of the pEPSCs into preimplantation embryos and after 48 hours of 149 
culture, pEPSCs (marked by EF1a-H2B-mCherry) had colonized both the 150 
trophectoderm and inner cell mass of the blastocyst (Extended Data Fig. 5a). 151 
Following the transfer of the chimeric embryos to pseudo-pregnant recipient sows, a 152 
total of 45 conceptuses were harvested from 3 litters at days 26-28 of gestation 153 
(Supplementary Table 2, Extended Data Fig. 5b). Flow cytometry of single cells 154 
collected from the embryonic and extraembryonic tissues of the chimeras revealed the 155 
presence of mCherry+ cells in 7 conceptuses (Extended Data Fig. 5c, Supplementary 156 
Table 3 and 4):  mCherry+ cells in both the placenta and embryonic tissues in 2 157 
chimeras (#8 and #16); only in embryonic tissues of 3 chimeras (#4, #21 and #34); 158 
and exclusively in the placenta of 2 chimeras (#3 and #6). Genomic DNA PCR assays 159 
detected mCherry DNA only in those seven mCherry+ chimeras, but not in any other 160 
conceptuses (Extended Data Fig. 5d, Supplementary Table 3 and 4).  Despite the 161 
overall low contribution from the donor mCherry+ cells, they were found in multiple 162 
host embryonic tissues and organs and expressed the appropriate tissue lineage 163 
markers: SOX2, TUJ1, GATA4, SOX17, AFP and α-SMA (Fig. 1f-g and Extended 164 
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Data Fig. 5e-f). In placental cells, mCherry was co-detected with the trophoblast 165 
markers PL-1 and KRT7 (Extended Data Fig. 5f).   166 
We next tested if pEPSCs had the potential to produce PGC-like cells (PGCLCs) in 167 
vitro, similar to mouse and human pluripotent stem cells [24-26]. In early-primitive 168 
streak (PS)-stage pig embryos (E11.5–E12), the first cluster of pig PGCs can be 169 
detected as SOX17+ cells in the posterior end of the nascent primitive streak, and 170 
these cells later co-express OCT4, NANOG, BLIMP1 and TFAP2C [25]. NANOS3 is 171 
an evolutionarily conserved PGC-specific factor [27, 28] and human NANOS3 172 
reporter cells have been used for studying PGCLCs from pluripotent stem cells [25, 173 
26]. To facilitate identification of putative pig PGCLCs, we targeted the H2B-174 
mCherry reporter cassette to the 3’ UTR of the NANOS3 locus in pEPSCsEmb (Line 175 
K3, male) (Extended Data Fig. 6a). After expressing the SOX17 transgene transiently 176 
for 12 hours, the NANOS3 reporter pEPSCsEmb were allowed to form embryoid bodies 177 
(EBs) (Extended Data Fig. 6b), which generated cell clusters co-expressing NANOS3 178 
(mCherry+) and tissue-nonspecific alkaline phosphatase (TNAP, a PGC marker) in 3-179 
4 days (Fig. 2a).  180 
The derivation of putative pig PGCLCs was BMP2/4 dependent, as removal of BMP2 181 
from the EB culture or inhibition of the BMP2/4 signaling by inhibitor LDN-193189 182 
abrogated the formation of mCherry+/TNAP+ cell clusters (Fig. 2a). Expressing 183 
NANOG, BLIMP1 or TFAP2C transgenes in pEPSCs, either individually or in 184 
combinations, had no effect on the preponderance of NANOS3+ cells (Extended Data 185 
Fig. 6c), which was different from the reported derivation of human PGCLCs [25]. 186 
However, co-expression of SOX17 with BLIMP1, but not NANOG or TFAP2C, 187 
increased the population of NANOS3+ cells (Extended Data Fig. 6c).  188 
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The mCherry+ (NANOS3+) putative PGCLCs in the EBs expressed PGC genes 189 
NANOS3, BLIMP1, TFAP2C, CD38, DND1, KIT and OCT4 [25], which was detected 190 
in RT-qPCR and was confirmed in immunofluorescence at single cell resolution  (Fig. 191 
2b-c, and Extended Data Fig. 6d). Specific RNA-seq analysis of the 192 
mCherry+/NANOS3+ cells revealed expression of early PGC genes (OCT4, NANOG, 193 
LIN28A, TFAP2C, CD38, DND1, NANOS3, ITGB3, SOX15 and KIT), and reduced 194 
SOX2 expression (Fig. 2d-e, Supplementary Table 5) [26]. During the PGC derivation 195 
from human ESCs, cells undergo global DNA demethylation, which is accompanied 196 
by upregulation of TETs and down-regulation of DNMT3A/B [26]. Similarly, relative 197 
to the parental pEPSCsEmb, DNMT3B was down-regulated in pig mCherry+/NANOS3+ 198 
cells, whereas TET1/2 were up-regulated (Fig. 2e-f, Supplementary Table 5).  199 
The findings that inhibition of SRC and Tankyrases is sufficient to convert mouse 200 
ESCs to mEPSCs [1] and that the same two inhibitors are required for the generation 201 
of pEPSCs raise the possibility that similar in vitro culture conditions may also work 202 
for deriving and maintaining EPSCs of other mammalian species. Four established 203 
human ES cell (hESC) lines (H1, H9, M1 and M10 cells) were cultured in pEPSCM 204 
and passaged up to three times. The cells displayed diverse morphologies and 205 
heterogeneous expression of OCT4 (Extended Data Fig. 7a). Removing ACTIVIN A 206 
(20ng/ml) from pEPSCM led to fewer cell colonies derived from H1 (<1.0%) and M1 207 
(5.0%) ESC lines, and none from H9 or M10 (Extended Data Fig. 7a), an observation 208 
consistent with the inherent between-line heterogeneity of human ESCs [29, 30]. With 209 
further refinement of the culture condition (For example, replacing A-419259 with 210 
another SRC inhibitor WH-4-023 in hEPSCM, see Methods), morphologically 211 
homogenous and stable cell lines were established from single-cell sub-cloned H1 212 
(H1-EPSCs) and M1 cells (M1-EPSCs) (Fig. 3a). Karyotype analysis of H1 and M1 213 
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cells grown in hEPSCM revealed genetic stability (at passage 25, Extended Data Fig. 214 
7b). When human primary iPSC colonies reprogrammed by the six-factor system [31] 215 
were directly cultured in hEPSCM, around 70% picked colonies could be established 216 
into stable iPSC lines (iPSC-EPSCs). (Extended Data Fig. 7c). These iPSCs expressed 217 
pluripotency markers with no obvious leakiness of the exogenous reprogramming 218 
factors (Extended Data Fig. 7d-e). The H1-EPSCs proliferated more robustly than the 219 
H1 ESCs cultured in standard FGF-containing medium (H1-ESC) or in the naïve 220 
5i/L/A conditions (H1-naïve ESC) [21] (Extended Data Fig. 7f), and were tolerant of 221 
single cell passaging with a 10% single cell sub-cloning efficiency in the transient 222 
presence of ROCKi. Cell survival at passaging was substantially improved in the 223 
presence of 5.0ng/ml ACTIVIN A or by splitting the cells at higher density. Human 224 
EPSCs expressed pluripotency genes (OCT4, SOX2, NANOG, REX1 and SALL4) at 225 
higher levels than the H1-ESCs (Extended Data Fig. 7d) but minimal levels of lineage 226 
markers (EOMES, GATA4, GATA6, T, SOX17 and RUNX1) (Extended Data Fig. 7g). 227 
Expression of core pluripotency factors and surface markers in human EPSCs was 228 
confirmed by immunostaining (Extended Data Fig. 7h). H1-EPSCs differentiated to 229 
derivatives of the three somatic germ layers in vitro and in vivo (Extended Data Fig. 230 
7i-j). Moreover, H1-EPSCs were successfully differentiated to PGCLCs using the in 231 
vitro conditions developed for germ cell competent hESCs or iPSCs [25, 26] 232 
(Extended Data Fig. 7k-l).  233 
Our results demonstrate that human and pig EPSCs could be derived and maintained 234 
using the similar set of small molecule inhibitors. Global gene expression profiling 235 
revealed that pEPSCs and hEPSCs clustered together, but were distinct from human 236 
primed ESCs or PFFs [1, 21] (Fig. 3b, Extended Data Fig. 8a and Supplementary 237 
Table 6-7). Both pig and human EPSCs expressed high levels of key pluripotency 238 
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genes, low levels of the somatic cell lineage genes, SOX1, PAX6, T, GATA4 and 239 
SOX7, and in general placenta-related genes such as PGF, TFAP2C, EGFR, SDC1 240 
and ITGA5 (Extended Data Fig. 8b-c). Consistent with the high level of global DNA 241 
methylation of pEPSCs and hEPSCs (Extended Data Fig. 8d), DNA methyltransferase 242 
genes DNMT1 and DNMT3A and DNMT3B were highly expressed, whereas TET1, 243 
TET2 and TET3 expressed at lower levels (Extended Data Fig. 8e). Among the highly 244 
expressed 76 genes (>8-fold increase) in H1-EPSC in comparison to H1-ESCs, 17 245 
genes encode histone variants with 15 belonging to the histone cluster 1 (Fig. 3c and 246 
Supplementary Table 8). Interestingly, these histone genes were expressed at low 247 
levels in 5i and primed human ESCs but were highly expressed in human 8-cell and 248 
morula stage embryos (Fig. 3d). These histone genes were also discovered to be 249 
expressed at significantly higher levels in additional hEPSC lines when compared 250 
with the same cells cultured either in the conventional human ESC medium (FGF) or 251 
5i (naïve) medium (Fig. 3e). The biological significance of high histone gene 252 
expression in hEPSCs and in human 8-cell and morula embryos remains to be 253 
explored. Single cell RNA-seq (scRNAseq) of pig and human EPSCs revealed 254 
uniform expression of the core pluripotency factors: OCT4, SOX2, NANOG and 255 
SALL4 (Fig. 3f), and substantially homogenous cell cultures (Fig. 3g). At the single-256 
cell level, mouse EPSCs were enriched for transcriptome of 4-cell to 8-cell 257 
blastomeres [1], whereas hEPSCs were more similar to human 8-cell to morula stage 258 
embryos [32, 33] (Fig. 3h, and Extended Data Figure 8f), which is in line with the 259 
histone gene expression profiles (Fig. 3d). Interestingly, transcriptome analysis also 260 
revealed low expression levels of naïve pluripotency factors such as KLF2 in EPSCs 261 
(Fig. 3f and Extended Data Fig. 8b), which is not expressed in human early 262 
preimplantation embryos [34]. Although KLF2, TET1, TET2 and TET3 were weakly 263 
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expressed in EPSCs (Extended Data Fig. 8b), their promoter regions were decorated 264 
with active H3K4m3 histone marks (Extended Data Fig. 8g). In contrast to 265 
pluripotency genes, the cell lineage gene loci (e.g. CDX2, GATA2, GATA4, SOX7 and 266 
PDX1) had high H3K27me3 and low H3K4me3 marks, respectively (Fig. 3i and 267 
Extended Data Fig. 8g).  268 
Human EPSCs and porcine EPSCs shared similar signalling requirements revealed by 269 
removing individual components from the culture medium. Removal of the SRC 270 
inhibitor WH-4-023 or A-419259 reduced expression of pluripotency factors in both 271 
EPSCs (Extended Data Fig. 9a-d). Similar to mEPSCs [1], XAV939 enhanced 272 
AXIN1 protein content (Extended Data Fig. 9e), and reduced canonical WNT 273 
activities in both EPSCs (Extended Data Fig. 9f). Withdrawal of XAV939 caused 274 
collapse and differentiation of these EPSCs (Extended Data Fig. 9a-b, 9d, and 9g-k). 275 
SMAD2/3 were phosphorylated in EPSCs (Extended Data Fig. 9e). Either removing 276 
ACTIVIN A from pEPSCM or adding the TGFβ inhibitor SB431542 resulted in 277 
massive cell loss and down-regulation of pluripotency factors in pEPSCs (Extended 278 
Data Fig. 9a, 9g, 9h and 9j), whereas in human EPSCs, the TGFβ inhibitor SB431542 279 
induced rapid cell differentiation with preferential expression of trophoblast lineage 280 
transcription factor genes CDX2, ELF5 and GATA2 (Extended Data Fig. 9b, 9i and 281 
9k). At a relatively low concentration of exogenous ACTIVIN A (5.0ng/ml), hEPSCs 282 
showed a stronger propensity for embryonic mesendoderm lineage differentiation as 283 
demonstrated by higher lineage marker expression and production of NANOS3-284 
tdTomato+ cells [25] (Extended Data Fig. 9l-n). Removing CHIR99021 and Vitamin 285 
C from pEPSCM did not affect pluripotency gene expression but reduced the number 286 
of colonies from single cells (Extended Data Fig. 9a and 9h), whereas a high 287 
CHIR99021 concentration (3.0µM, H-CHIR99021) induced pEPSCEmb cell 288 
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differentiation (Extended Data Fig. 9a, 9h and 9j), similar to that in rat or human 289 
naïve cells [23, 35]. JNK and BRAF inhibition may improve the culture efficiency, 290 
but was not essential (Extended Data Fig. 9h-i). In hEPSCs, the requirements for 291 
CHIR99021 and Vc were similar to pEPSCs (Extended Data Fig. 9a-b and 9h-i).  292 
 293 
The differentiation of hEPSCs to trophoblasts was tracked by expression of CDX2-294 
Venus reporter (T2A-Venus inserted into the 3’ UTR of the CDX2 locusExtended Data 295 
Fig. 10a). Inhibiting TGFβ by SB431542 resulted in ~70% of the CDX2 reporter cells 296 
being CDX2-Venus+ (Fig. 4a), whereas essentially no CDX2-Venus+ cells were 297 
detected if the reporter cells were cultured in FGF or under the 5i naïve ESC 298 
conditions. Expression of trophoblast genes such as CDX2, GATA3, ELF5, KRT7, 299 
TFAP2C, PGF, HAND1 and CGA rapidly increased in differentiating H1-EPSCs and 300 
iPSC-EPSCs but not H1-ESCs or H1-5i naïve cells (Fig. 4b). Addition of BMP4, 301 
which promotes differentiation of human ESCs to putative trophoblasts [36], induced 302 
expression of trophoblast genes at a much higher level in H1-EPSCs and iPSC-EPSCs 303 
than in H1-ESCs or H1-5i naïve ESCs (Extended Data Fig. 10b). Inhibiting FGF and 304 
TGFβ signalling while in parallel activating BMP4 effectively induced trophoblast 305 
differentiation in FGF-cultured human ESCs [37, 38]. Under this condition, 306 
expression of trophoblast genes, especially the late trophoblast genes GCM1, CGA 307 
and CGB, was much higher in H1-EPSCs than in H1-ESCs, whereas naïve 5i hESCs 308 
displayed no trophoblast differentiation (Extended Data Fig. 10c). Global gene 309 
expression analysis demonstrated that under TGFβ signalling inhibition H1-EPSCs 310 
and iPSC-EPSCs followed a distinct trajectory from the H1-ESCs (Fig. 4c), and that 311 
in cells differentiated from EPSCs, but not from H1-ESCs, important trophoblast 312 
development or function genes were highly expressed including BMP4 (day 2-4 313 
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differentiation), genes of human endogenous retrovirus-encoded envelope protein 314 
Syncytin-1 (ERVW-1) and Syncytin-2 (ERVFRD-1) that promote cytotrophoblast 315 
fusion into syncytiotrophoblast, the maternally expressed gene p57 (encoded by 316 
CDKN1C) which is expressed in trophoblast cells and is essential for normal placenta 317 
development [39, 40], CD274 (encoding PD-L1 or B7-H1) that modulate immune cell 318 
activities, and EGFR which is important in human trophoblast stem cells (hTSCs) 319 
[41] (Extended Data Fig. 10d and Supplementary Table 6).    320 
To further infer the identity of the differentiated hEPSCs by TGFβ inhibition, we 321 
performed Pearson correlation coefficient analysis of cells differentiated from H1-322 
EPSCs, iPSC-EPSCs or H1-ESCs with external reference samples including primary 323 
human trophoblasts (PHTs) and the human placenta tissues [38], which again 324 
revealed the similarity between cells differentiated from hEPSCs and PHTs and the 325 
placenta (Extended Data Fig. 10e). The cells differentiated from H1-EPSCs by TGFβ 326 
inhibition expressed human trophoblast specific miRNAs (C19MC miRNAs: hsa-327 
miR-525-3p, hsa-miR-526b-3p, hsa-miR-517-5p, and hsa-miR-517b-3p) [42] 328 
(Extended Data Fig. 10f-g), displayed DNA demethylation at the ELF5 locus [43, 44] 329 
(Extended Data Fig. 10h), and produced abundant amounts of placental hormones 330 
(Extended Data Fig. 10i-j).  331 
When hEPSCs (ESC-converted-EPSCs and iPSC-EPSCs) were cultured in human 332 
trophoblast stem cell (hTSC) conditions [41] under low cell density (2,000 333 
cells/3.5cm dish), colonies with TSC morphology formed after 7-9 days (Fig. 4d). 334 
These colonies were picked and expanded into stable cell lines under hTSC condition 335 
with up to 30% line establishment efficiency (Fig. 4d). On the other hand, no hTSC 336 
lines could be established from standard human ESCs or human naïve ESCs (H1 and 337 
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M1 ESC). The hEPSC-derived TSCs expressed trophoblast transcription regulators: 338 
GATA2, GATA3 and TFAP2C, down-regulated pluripotency markers and could 339 
differentiate to both multi-nucleated syncytiotrophoblasts (ST) and HLA-G+ 340 
extravillous trophoblasts (EVT) following the published protocols [41] (Fig. 4e, 4f 341 
and 4g and Extended Data Fig.11a-e). Although both pig and human EPSCs did not 342 
express placenta development-related genes such as PGF, TFAP2C, EGFR, SDC1 343 
and ITGA5, at high levels (Extended Data Fig. 8c), both cells had high H3K4me3 at 344 
these loci (Extended Data Fig. 11f), underpinning EPSCs’ enhanced trophoblast 345 
potency. In line with the similarities between human and pig EPSCs, under human 346 
TSC condition, stable TSC-like lines could also be derived from pig EPSCsEmb 347 
(Extended Data Fig. 11g-i). Our results therefore provide compellingly evidence that 348 
human and pig EPSCs possessed expanded differentiation potential that encompasses 349 
the trophoblast lineage.  350 
One of the key mechanisms for the derivation and maintenance of EPSCs of mouse, 351 
pig and human is blocking poly(ADP-ribosyl)ation activities of PARP family 352 
members TNKS1/2 using small molecule inhibitors such as XAV939 [45, 46]. In 353 
human cells, poly(ADP-ribose) is removed by poly(ADP-ribose) glycohydrolase 354 
(PARG) and ADP-ribosylhydrolase 3 (ARH3) [47]. Genetic inactivation of Parp1/2 355 
and TNKS1/2 in the mouse caused trophoblast phenotypes, whereas inactivating Parg 356 
led to loss of functional trophectoderm and TSCs [48, 49]. We tested whether PARG 357 
was of any relevance to hEPSCs developmental potential to trophoblasts. In hEPSCs, 358 
PARG-deficiency did not appear to cause noticeable changes in EPSC culture but 359 
adversely affected trophoblast differentiation (Extended Data Fig. 12a-e), which may 360 
indicate an evolutionally conserved mechanism for EPSCs and trophoblast 361 
development from the mouse to human.  362 
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 363 
EPSCs of mouse, pig and human can now be established under similar in vitro culture 364 
conditions. These stem cells share unique molecular features and possess expanded 365 
potency for both embryonic and extraembryonic cell lineages that are generally not 366 
seen in the conventional embryo-derived or induced pluripotent stem cells. EPSCs 367 
may therefore represent a unique state of cellular potency. The successful generation 368 
of EPSCs produces new tools for investigation of embryonic development, and opens 369 
a wealth of avenues for translational research in biotechnology, agriculture, and 370 
genomics and regenerative medicine. 371 
 372 
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Figure legends 552 
Figure 1. Derivation and characterization of pig EPSCs. a. Left: Schematic diagram 553 
of establishment of pig EPSCEmb lines from German Landrace day-5 in vivo derived 554 
blastocysts on STO feeder cells in pEPSCM, and of pEPSCiPS lines by 555 
reprogramming German Landrace PFFs and China TAIHU OCT4-Tdtomato knock-in 556 
reporter (POT) PFFs. Right panels: images of established EPSC lines, and 557 
fluorescence image of Td-tomato expression in POT-pEPSCiPS. Three EPSCEmb lines 558 
(Male: K3 and K5; Female K1) and three pEPSCiPS lines (#10, #11) were extensively 559 
tested in this study. These EPSC lines behaved similarly in gene expression and 560 
differentiation. b. Bisulphite sequencing analysis of CpG sites in the OCT4 and 561 
NANOG promoter regions in PFFs, pEPSCiPS and pEPSCEmb. c. Gene expression in 562 
embryoid bodies (EBs, day 7) of pEPSCsEmb. Genes of both embryonic and extra-563 
embryonic cell lineages were examined in RT-qPCR. Data are mean ± s.d. (n = 3). d. 564 
Tissue composition of pEPSCEmb teratoma sections (H&E staining): Examples of 565 
glandular epithelium derived from endoderm (i), cartilage derived from mesoderm 566 
(ii), immature neural tissue derived from ectoderm, which forms well defined neural 567 
tubes (iii), and large multinucleated cells reminiscent of torphoblasts (arrows in iv). e. 568 
Expression of PL-1 in multi-nucleated cells in the pEPSCEmb teratoma sections 569 
revealed by immunostaining. f. Schematic diagram of day 25-27 pig chimera 570 
embryos. The circles mark the areas where tissues taken for immunofluorescence 571 
analysis (Additional chimeras tissues were analysed in Extended Data Fig. 5e, 5f):  i, 572 
brain; ii, liver. g.  Detection of pEPSC descendants in the brain 573 
(H2BmCherry+SOX2+) and the liver (H2BmCherry+AFP+) cells in chimera #16. 574 
Nuclei were stained with DAPI. Boxed areas are shown in higher magnification.  575 
 21
Figure 2. In vitro generation of PGC-like cells from pEPSCsEmb. a. Induction of 576 
pPGCLC by transiently expressing SOX17 in NANOS3-H2BmCherry reporter 577 
pEPSCs. The presence of H2BmCherry+TNAP+ cells in embryoid bodies (EBs) were 578 
analysed by FACS. b. RT-qPCR analysis of PGC genes in day 3 EBs following 579 
pPGCLC induction. c. Immunofluorescence analysis PGC factors in the sections of 580 
day 3-4 EBs of pPGCLC induction. The H2BmCherry+ cells co-expressed NANOG, 581 
OCT4, BLIMP1, TFAP2C and SOX17. Nuclei were stained with DAPI. Experiments 582 
were repeated at least three times. d. RNAseq analysis (Heat map) of sorted 583 
H2BmCherry+ of pPGCLC induction shows expression of genes associated with 584 
PGCs, pluripotency or somatic lineages (mesoderm, endoderm, and gonadal somatic 585 
cells). e. Pair-wise gene expression comparison between pEPSCsEmb and pPGCLCs. 586 
Key up-regulated (red) and down-regulated (blue) genes were highlighted. f. Bar plot 587 
shows expression of genes related to DNA methylation in pPGCLCs and the parental 588 
pEPSCsEmb. Data are from RNAseq of sorted H2BmCherry+ of pPGCLC induction.  589 
Figure 3. Establishment of human EPSCs. a. Images of the established H1-EPSCs or 590 
M1-EPSCs (passage 25). b. Principal component analysis (PCA) of bulk RNA-seq 591 
gene expression data of human, pig and mouse EPSCs, human primed and naïve 592 
ESCs, PFFs. pEPSCPar: EPSC lines from parthenogenetic embryos; E14 and AB2-593 
EPSCs are mouse EPSCs. c. Pair-wise comparison of gene expression between H1-594 
ESCs and H1-EPSCs, showing the highly expressed genes (>8 folds) in hEPSCs (total 595 
76, red dots) and representative histone genes (blue dots). d. Heatmap showing 596 
expression of selected histone genes in H1-ESCs, H1-EPSCs, iPSC-EPSCs and 597 
human naïve (5i) ESCs, and human preimplantation embryos. The RNAseq data of 598 
human primed and naïve ESCs were obtained from Theunissen, T. W. et al. (Cell 599 
Stem Cell 2014) whereas embryo cell data were from Yan L., et al (Nat Struct Mol 600 
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Biol. 2013). e. RT-qPCR analysis of expression of four histone 1 cluster genes in 601 
seven human ESC or iPSC lines cultured in the three conditions: FGF (primed), 5i 602 
(naïve) and EPSCM (EPSC). Hipsci iPSC lines were obtained from the Hipsc project 603 
at the Wellcome Trust Sanger Institute (http://www.hipsci.org): #1, HPSI1113i-604 
bima_1; #2, HPSI1113i-qolg_3; #3, HPSI1113i-oaaz_2; #4, HPSI1113i-uofv_1. 605 
Relative expression levels, normalized to GAPDH, are compared against that in the 606 
cells cultured in the FGF condition. Data are mean ± s.d. (n = 3). Experiments were 607 
repeated at least three times. f. Violin plots show scRNAseq expression of 608 
pluripotency genes in pEPSCsEmb (top panel) and human H1-EPSCs (lower panel). g. 609 
PCA of global gene expression pattern (by scRNAseq) of pEPSCsEmb (left panel) and 610 
H1-EPSCs (right panel). h. PCA and comparison of gene expression from scRNAseq 611 
of human H1-EPSCs and human preimplantation embryos (Yan L. 2013 Nat Struct 612 
Mol Biol. See Methods for details) . i. ChIP-seq analysis of H3K27me3 and 613 
H3K4me3 marks at pluripotency gene loci in pEPSCsEmb and human H1-EPSCs.  614 
Figure 4. Trophoblast differentiation potential of human EPSCs. a. Left panel: 615 
diagram of hEPSCs to trophoblast under TGFβ inhibition. See Methods for more 616 
details. Right panel: differentiation the CDX2-H2B-Venus reporter EPSCs to 617 
trophoblasts detected in flow cytometry. The CDX2-H2B-Venus reporter EPSCs were 618 
also cultured in conventional FGF-containing hESCs medium or 5i-naïve medium and 619 
were subsequently subjected to the same differentiation condition and examined in 620 
flow cytometry. Cells were collected 4 days after TGFβ inhibition. b. The dynamic 621 
changes in the expression of trophoblast genes during hEPSC differentiation at 622 
several time points assayed by RT-qPCR. Data are mean ± s.d. (n = 3). Experiments 623 
were repeated at least three times. c. tSNE analysis of RNA-seq data of the 624 
differentiated cells from H1-ESCs, H1-EPSCs, or iPSC-EPSCs treated with the TGFβ 625 
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inhibitor SB431542. RNAs were sampled at Day 0-12 during differentiation. The 626 
differentiation trajectory of H1-EPSCs and hiPSC-EPSCs is distinct from that of H1-627 
ESCs. d. Phase-contrast images of primary TSC colonies formed from individual 628 
hEPSCs (left) and of TSCs at passage 7 (right). e. Expression of trophoblast 629 
transcription factors GATA3 and TFAP2C, and KRT7 in EPSC-TSCs detected by 630 
immunostaining. Nuclei were stained with DAPI. Similar results were obtained with 631 
four independent EPSC-TSC lines. f. Expression of SDC1 in syncytiotrophoblasts 632 
differentiated from EPSC-TSCs detected by immunofluorescence. DAPI stains the 633 
nucleus. g. Detection of HLA-G in hESCs, hEPSCs, hTSCs, and the cells 634 
differentiated from hTSCs following the EVT protocol (Okae, H, et al. Cell Stem cell 635 
2018). The choriocarcinoma cells JEG-3 that are representatives of extravillous 636 
trophoblasts and express HLA-G, and JAR that are representatives of villous 637 
trophoblast cells so do not express any HLA molecules (Apps, R., et al. Immunology 638 
2009), were used as the positive and negative control, respectively. Experiments were 639 
repeated at least three times. 640 
 641 
 642 
 643 
 644 
 645 
 646 
 647 
 648 
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Extended Data Figures 649 
Extended Data Figure 1. Establishment of new Dox-dependent pig iPSC lines for 650 
screening culture conditions. a. Doxycycline (Dox)-inducible expression of 651 
Yamanaka factors OCT4, MYC, SOX2 and KLF4, together with LIN28, NANOG, 652 
LRH1 and RARG in wild type German Landrace PFFs. cDNAs were cloned into 653 
piggyBac (PB) vectors and transfected into PFFs with a plasmid expressing the PB 654 
transposase for stable integration of the expression cassette into the pig genome. 655 
OMSK: 4 Yamanaka factors OCT4, MYC, SOX2 and KLF4; N-LIN: NANOG and 656 
LIN28; RL: RARG and LRH1. After 8-10 days of Dox induction, primary colonies 657 
appeared. Those colonies were single-cell passaged in the presence of Dox in M15 658 
(15% fetal calf serum). b. Co-expression of LIN28, NANOG, LRH1 and RARG 659 
substantially increased the number of reprogrammed colonies. *p value < 0.05: the 8-660 
factor induced colonies from 250,000 PFFs in comparison to those of using 4 661 
Yamanaka factors. c. Reprogramming of the porcine OCT4-tdTomato knock-in 662 
reporter (POT) TAIHU PFFs to iPSCs. After 8 days of Dox induction, the primary 663 
colonies appeared, which were tdTomato+ under fluorescence microscope. The 664 
primary colonies were picked and expanded in the presence of Dox. Shown on image 665 
are P3 cells of bright field and fluorescence. d. The iPSCs lines expressed key 666 
pluripotency genes in RT-qPCR analysis. The iPSC lines #1 and #2, and iPSC #3 and 667 
#4 were from wild type German Landrace and TAIHU POT PFFs, respectively. Gene 668 
expression in pig parthenogenetic blastocysts was used as the control. e. RT-qPCR 669 
analysis of expression of the exogenous reprogramming factors in iPSCs either in the 670 
presence of Dox or 3 days after its removal. f. Differentiation of iPSC cells once Dox 671 
was removed from the culture medium. The images were cells 3 days after Dox 672 
removal. The POT iPSCs became Td-tomato negative. g. RT-qPCR analysis of the 673 
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expression of endogenous pluripotency genes in iPSC cultured with or without Dox. 674 
h. Expression of lineage genes in the pig iPSCs 5-6 days after DOX removal. Gene 675 
expression was measured by RT-qPCR. Data are mean ± s.d. (n = 3). Experiments 676 
were repeated at least three times. 677 
Extended Data Figure 2. Identification of culture conditions for pig EPSCs. a. The 678 
Dox-dependent iPSC clone #1 of German Landrace strain was used in the screens. 679 
Small molecule inhibitors and cytokines were selected for various combinations. Cell 680 
survival, cell morphology, and expression of endogenous OCT4 and NANOG were 681 
employed as the read-outs. b-h. The relative expression levels of endogenous OCT4 682 
and NANOG in the survived cells after 6 days of culture in different basal media 683 
supplemented with inhibitors and cytokines combinations: b. M15 medium without 684 
Dox; c. N2B27 basal medium without Dox; d. 20% KOSR medium without Dox; e. 685 
AlbumMax II basal medium without Dox; f. N2B27 basal medium with Dox; g. Four 686 
individual basal medium with Dox (M15: 411-431; N2B27: 432-453; KOSR: 454-687 
475; AlbumMax II: 476-497); h. N2B27 basal medium without Dox. 2i: GSK3i and 688 
MEKi; t2i: GSK3i, MEKi and PKCi (Takashima, Y., et al. 2014 Cell); 4i: GSK3i, 689 
MEKi, JNKi and p38i (Irie, N., et al 2015 Cell); 5i: GSK3i, MEKi, ROCKi, BRAFi 690 
and SRCi (Theunissen, T. W., et al. 2014 Cell Stem Cell); mEPSCM: GSK3i, MEKi, 691 
JNKi, XAV939, SRCi and p38i ( Yang J ., et al. 2017 Nature); Details of the inhibitor 692 
combinations are presented in Supplementary Table 1. The experiments in Extended 693 
Data Figure 2h were repeated at least three times. 694 
Extended Data Figure 3. Establishment of pig EPSCs by reprogramming PFFs or 695 
from pre-implantation embryos. a. Images showing the toxicity of MEKi, PKCi and 696 
p38i to the pig iPSCs in M15 plus Dox. b. Endogenous pluripotency gene expression 697 
in both wild type and OCT4-TdTomato reporter iPSCs in the absence of Dox in 698 
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pEPSCM (#517 minimal condition, Extended Data Fig. 2h). Gene expression was 699 
compared to that in porcine parthenogenetic blastocysts. Data are mean ± s.d. (n = 3). 700 
c. Images of wild type and OCT4-Tdtomato reporter iPSCs in pEPSCM without Dox. 701 
Gene expression was compared to that in porcine parthenogenetic blastocysts. d. 702 
Detection of leaky expression of the exogenous reprogramming factors by RT-PCR. 703 
About half of the iPSC lines did not have detectable leaky expression. e. Schematic 704 
diagram of reprogramming PFFs to establish EPSC lines in pEPSCM. f. Two newly 705 
established WT pEPSCiPS lines (#10 and #11) were examined for the expression of 706 
endogenous pluripotency genes and the exogenous reprogramming factors. Data are 707 
mean ± s.d. (n = 3). g. Day-10 outgrowth from a porcine early blastocyst in pEPSCM 708 
supplemented with ROCK inhibitor. The outgrowths were picked at day 10-12 for 709 
dissociation and re-plating to establish stable lines. h. Representative images of the 710 
pEPSCEmb (Line K3) established from pig in vivo derived embryos. Experiments were 711 
repeated at least three times. 712 
Extended Data Figure 4. Characterisation of pEPSCs. a. pEPSCEmb (Line K3) 713 
retained the normal karyotype after 25 passages (10/10 metaphase spreads examined 714 
were normal). Two additional lines examined also had the normal karyotype after 715 
more than 25 passages. b. Immunostaining detection of pluripotency factors and 716 
markers, SSEA-1 and SSEA-4, in pEPSCEmb and pEPSCiPS. c. Active Oct4 distal 717 
enhancer in pig EPSCEmb and EPSCiPS.  The mouse Oct4 distal and proximal enhancer 718 
constructs were used in the luciferase assay. Data are mean ± s.d. (n = 3). d. Efficient 719 
genome-editing in pEPSCsEmb. Knocking-in the H2B-mCherry expressing cassette 720 
into pig ROSA26 locus was facilitated by the CRISPR/Cas9. Out of 20 colonies 721 
picked for genotyping, 5 were correctly targeted. Importantly, the targeted pEPSCs 722 
retained the normal karyotype. e. Bright field and fluorescence images of the 723 
 27
pEPSCEmb colonies with the H2B-mCherry correctly targeted to the ROSA26 locus. f. 724 
in vitro differentiation of pEPSCEmb to cells of the three somatic germ layers and the 725 
trophectoderm lineage (KRT7+).  726 
Extended Data Figure 5. In vivo differentiation potential of pEPSCs. a. Participation 727 
of pEPSCs in preimplantation embryo development. H2B-mCherry-expressing donor 728 
pEPSCsiPS were injected to day 5 host pig parthenogenetic embryos, which were 729 
allowed to develop into blastocysts. Arrow indicates donor cell’s location in the TE. 730 
H2BmCherry+ donor cells were found in both the inner cell mass and the 731 
trophectoderm. b. Whole-mount fluorescence and bright field images of 26-day pig 732 
embryos from the preimplantation embryos injected with H2BmCherry+ pEPSCsEmb, 733 
showing the possible presence of mCherry+ cells in chimera #21. c. Tissues were 734 
dissected out from four areas of each embryo, head (a), trunk (b) and tail (c), and the 735 
placenta (d), which were dissociated to single cells for flow cytometry analysis to 736 
detect donor H2BmCherry+ cells and for making genomic DNA samples for PCR 737 
analysis. d. PCR genotyping for mCherry DNA using the genomic DNA samples 738 
described above. mCherry DNA was only detected in the embryos that were 739 
mCherry+ by flow cytometry analysis. e. Schematic diagram of day 25-27 pig chimera 740 
embryos. The circles mark the tissue areas that were taken for immunostaining 741 
analysis as shown in the main Fig. 1f. iii: neural tissues; iv: endoderm derivatives; v: 742 
smooth muscle; vi: the placenta. f. Co-localisation of H2BmCherry with lineage 743 
markers in the mCherry+ fetuses and placentas using antibodies to TUJ1 (Chimera 744 
#16), SOX17 (Chimera #21), GATA4 (Chimeras #21), a-SMA (Chimera #21), KRT7 745 
and PL-1 (Chimera #6) on cryosections by immunofluorescence. 746 
Extended Data Figure 6. Differentiation of pEPSCs to pPGCLCs. a. Generation of 747 
the NANOS3-H2BmCherry reporter EPSCsEmb by targeting the H2B-mCherry cassette 748 
 28
to the NANOS3 locus. In the targeted allele, the T2A-H2B-mCherry sequence was in 749 
frame with the last coding exon of the pig NANOS3 locus with the stop codon TAA 750 
being deleted. We generated gRNA plasmids targeting specifically to the region 751 
covering the NANOS3 stop codon. We picked 15 colonies for genotyping, and 4 of 752 
them were correctly targeted ones. After expansion, those targeted pEPSCs were 753 
found retaining the normal karyotype. b. Diagram illustrating the strategy for 754 
expressing exogenous genes in pEPSCsEmb for pPGCLC specification and 755 
differentiation (see Methods for more details). c. Expressing NANOG, BLIMP1 and 756 
TFAP2C individually or in combination with SOX17 in the differentiation of 757 
NANOS3-H2BmCherry reporter EPSCsEmb to pPGCLCs (H2BmCherry+). d. RT-758 
qPCR analysis of PGC genes. RNA samples were prepared from day 3 EBs of 759 
pEPSCs that expressed transgenes individually or in combinations following the 760 
pPGCLC induction protocol in b. Relative expression levels are shown with 761 
normalization to GAPDH. Data are mean ± s.d. (n = 3). Experiments were repeated at 762 
least three times. 763 
Extended Data Figure 7. Establishment and characterisation of human EPSCs. a. 764 
Images of H1, H9, M1 and M10 human ESC colonies in pEPSCM or in pEPSCM 765 
minus Activin A. Expression of OCT4 was detected by immunostaining. b. Normal 766 
karyotype in H1-EPSCs and M1-EPSCs after 25 passages in hEPSCM (10/10 767 
metaphases scored were normal). c. Primary iPSC colony (top) and established 768 
cultures of iPSCs (bottom) in hEPSCM reprogrammed from human dermal fibroblasts 769 
by Dox-inducible expression of exogenous OCT4, MYC, KLF4, SOX2, LRH1 and 770 
RARG. d. The relative expression levels of pluripotency genes (POU5F1, SOX2, 771 
NANOG, REX1 and SALL4) in H1-ESCs, H1-naïve ESCs (5i), H1-EPSCs and iPSC-772 
EPSCs. *p value < 0.05 compared with H1-naïve ESCs (5i), H1-EPSCs and iPSC-773 
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EPSCs. Data are mean ± s.d. (n = 3). e. Detection of potential expression leakiness of 774 
the exogenous reprogramming factors by RT-qPCR. No obvious leakiness was found 775 
in the four established iPSC lines. f. The relative doubling time of H1-ESCs, H1-776 
naïve ESCs (5i), H1-EPSCs and iPSC-EPSCs. Data are mean ± s.d. (n = 3). *p value 777 
< 0.05. g. Expression of lineage markers (EOMES, GATA4, GATA6, T, SOX17 and 778 
RUNX1) in H1-ESCs, H1-naïve ESCs (5i), H1-EPSCs and iPSC-EPSCs. Data are 779 
mean ± s.d. (n = 3). h. Immunostaining of H1-EPSCs and iPSC-EPSCs for 780 
pluripotency factors and cell surface markers. i. In vitro differentiation of H1-EPSCs 781 
to the three somatic cell lineages. j. Teratomas from hEPSCs in immunocompromised 782 
mice showing by morphology the presence of cartilage (mesoderm. I), glandular 783 
epithelium (endoderm. II) and mature neural tissue (glia and neurons, ectoderm. III) 784 
in H&E staining. k. EBs of H1-EPSCs to PGCLCs immunostained for OCT4, 785 
BLIMP1 and SOX17. l. FACS analysis for expression of CD38 and TNAP on 786 
PGCLCs of H1-EPSCs. The induction of PGCLCs was performed on at least two 787 
independent human EPSC lines, and experiments were repeated at least three times. 788 
Extended Data Figure 8. Molecular features of human and porcine EPSCs. a. 789 
Hierarchical clustering of global gene expression data (RNA-seq) of human primed 790 
and naïve ESCs, EPSCs of human, pig and mouse. Correlation matrix was clustered 791 
using Spearman correlation and complete linkage. pEPSCPar: EPSC lines from porcine 792 
parthenogenetic embryos; E14 and AB2-EPSCs are mouse EPSCs. See Methods for 793 
details of data resources for this analysis. b. Expression of pluripotency and lineage 794 
genes in pig (left panel) and human (right panel) EPSCs. c. Expression of trophoblast 795 
related genes in pig (left panel) and human (right panel) EPSCs. d. Global DNA 796 
methylation levels in pig (left) and human (right) EPSCs. e. Expression of genes 797 
encoding enzymes in DNA methylation or demethylation in pig (left) and human 798 
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(right) EPSCs. Data are mean ± s.d. (n = 3). f. PCA of scRNAseq data of human H1-799 
EPSCs and that of human preimplantation embryos (data from Dang Y. et al 2016. 800 
Genome Biology. See Methods for more details). g. Histone modifications (H3K4me3 801 
and H3K27me3) at the loci for genes encoding enzymes involved in DNA 802 
methylation and demethylation and for lineage genes.   803 
Extended Data Figure 9. The requirement of individual components in the culture 804 
conditions for pig EPSCs and human EPSCs. a-b. The effects of removing individual 805 
inhibitors on gene expression in pEPSCsEmb and H1-EPSCs analysed by RT-qPCR. “-806 
SRCi, -XAV939, -ACTIVIN, -Vc, -CHIR99”: removing them individually from 807 
pEPSCM or hEPSCM; “+TGFBi, +H-CHIR99”: adding the TGFβ inhibitor 808 
SB431542, or a higher concentration of CHIR99021 (3.0 µM). c. Targeting the 809 
OCT4-H2B-Venus cassette into the OCT4 locus in H1-EPSCs. In the targeted allele, 810 
the T2A-H2B-Venus sequence was in frame with the last coding exon of the OCT4 811 
gene. The stop codon TGA was deleted. We genotyped 19 colonies, 5 of them were 812 
correctly targeted. d. The effects of removing the SRC inhibitor WH-4-023 or 813 
XAV939 from hEPSCM measured by Venus+ cells. The OCT4-H2B-Venus reporter 814 
EPSCs were cultured in the indicated conditions and were analysed for Venus 815 
expression by fluorescence microscopy or in flow cytometry. e. Western blot analysis 816 
of AXIN1 and phosphorylation of SMAD2/3 in porcine and human EPSCs. Both 817 
pEPSCEmb and H1-EPSCs had much higher levels of AXIN1. pEPSCEmb, H1-EPSCs 818 
and H1-naïve ESCs (5i) had higher levels of TGFβ signalling evidenced by higher 819 
pSMAD2/3 than in the differentiated (D) EPSCEmb or primed H1-ESCs. f. TOPflash 820 
analysis of the canonical Wnt signalling activities in porcine and human EPSCs. 821 
Removing XAV939 from pEPSCM (pEPSCM-X) or hEPSCM (hEPSCM-X) 822 
substantially increased TOPflash activity. *p < 0.05. RT-qPCR data are mean ± s.d. (n 823 
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= 3). Experiments were repeated at least three times. g. Bright-field and 824 
immunofluorescence images showing pEPSCsEmb cultured in pEPSCM or in 825 
pEPSCM with the indicated changes in its components. The cells were stained for 826 
OCT4. h-i. Quantitation of AP+ colonies formed from 2,000 pEPSCsEmb or H1-EPSCs 827 
on STO feeders in a 6-well plate. The colonies were scored for 5 consecutive passages 828 
to determine the effects of removing XAV939, Vitamin C or CHIR99021, or of 829 
adding a JNK inhibitor or a BRAF inhibitor. Data are mean ± s.d. (n = 3) and the 830 
experiments were repeated three times. j-k. RT-qPCR analysis of expression of 831 
lineage genes in pEPSCsEmb and hEPSCs when XAV939 or ACTIVIN A was 832 
removed from pEPSCM and hEPSCM or TGFB signalling was inhibited by 833 
SB431542. l. The effects of supplementing 5.0 ng/ml ACTIVIN A in hEPSCM on the 834 
expression of lineage genes in EBs formed from H1-EPSCs. Genes of mesendoderm 835 
lineage genes were substantially increased. *p < 0.05. m-n. Differentiation to 836 
PGCLCs from the NANOS3-Tdtomato reporter EPSCs cultured in hEPSCM either 837 
with or without 5.0ng/ml ACTIVIN A. Adding ACTIVIN A substantially increased 838 
PCGLCs measured in FACS (Tdtomato+). RT-qPCR analysis of PGCLC genes 839 
confirmed the increase of PCGLCs. *p < 0.05 in comparison to hEPSCM 840 
supplemented with ACTIVIN A. RT-qPCR data are mean ± s.d. (n = 3). Experiments 841 
were repeated at least three times. 842 
Extended Data Figure 10. Characterization of hEPSC trophoblast differentiation 843 
potential. a. Generation of the CDX2-H2BVenus reporter EPSC line. In the targeted 844 
allele, the T2A-H2BVenus sequence was in frame with the last coding exon of the 845 
human CDX2 gene. The TGA stop codon was deleted in the targeted allele. The 846 
reporter EPSCs were subsequently cultured in hEPSCM, in the standard FGF-847 
containing human ESC medium or in the 5i condition for human naïve ESCs, for 848 
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subsequent analyses. b. Trophoblast gene expression measured by RT-qPCR in cells 849 
induced to differentiate to trophoblasts by 4-day BMP4 treatment. Experiments were 850 
repeated at least three times. c. Trophoblast gene expression measured by RT-qPCR 851 
in hEPSC induced to differentiate to trophoblasts by SB431542 + PD173074 + 852 
BMP4. qRT-PCR data are mean ± s.d. (n = 3). Cells were collected at several time 853 
points for analysis. d. Heatmap shows expression changes of trophoblast genes in 854 
cells differentiated from H1-ESCs (green), H1-EPSCs (red) or iPSC-EPSCs (blue) 855 
(RNAseq data are in Supplementary Table 6). Cells were collected at several 856 
differentiation time points for RNAseq analysis. e. Pearson correlation coefficient of 857 
gene expression in cells differentiated from H1-ESCs, H1-EPSCs and iPSC-EPSCs 858 
(RNAseq data in Supplementary Table 6), with the published data of PHTu and PHTd 859 
(undifferentiated and differentiated human primary trophoblasts, respectively) and 860 
with human tissues. The details of these analyses are in Methods. f. Detection of the 861 
four C19MC miRNAs (hsa-miR-525-3p, -526b-3p, -517-5p, and -517b-3p) in cells 862 
differentiated from H1-EPSCs, H1-ESCs, H1-naïve ESCs (5i) and iPSC-EPSCs 863 
treated with SB431542 for six days. The choriocarcinoma cells JEG-3 that are 864 
representatives of extravillous trophoblasts and JAR that are representatives of villous 865 
trophoblast cells were used as the positive and negative control, respectively. g. The 866 
expressions of the same four miRNAs as presented above in the BMP4 (4-day) treated 867 
human EPSCs and human ESCs. The choriocarcinoma cells JEG-3 that are 868 
representatives of extravillous trophoblasts and JAR that are representatives of villous 869 
trophoblast cells were used as the positive and negative control, respectively. h. DNA 870 
demethylation in the promoter region of the ELF5 locus in cells differentiated from 871 
H1-EPSCs and other cells (6 days of SB431542 treatment). Cells from H1-ESCs, H1-872 
naïve ESCs (5i) did not have substantial DNA demethylation at the ELF5 promoter. i. 873 
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Secreted hormones from trophoblasts derived from H1-EPSCs induced by TGFβ 874 
inhibition (SB431542). VEGF, PLGF, sFlt-1and sEng were measured in the 875 
conditioned media of cells differentiated from EPSCs or ESC cultures upon 876 
SB431542 treatment over a 48h interval until day 16.  j. hCG secreted from 877 
trophoblasts from EPSCs or ESCs. hCG secreted from day-10 differentiated 878 
(SB431542 treatment) EPSCs and ESCs were measured by ELISA. *P < 0.05 879 
compared with H1-ESC. Data are mean ± s.d. (n = 3).  880 
Extended Data Figure 11. Derivation and characterisation of TS cells from human 881 
and pig EPSCs. a. RT-qPCR analysis of pluripotency and trophoblast stem cell genes 882 
in four EPSC-derived TSC lines and their parental hEPSCs. b. Phase-contrast and 883 
Hoechst staining images of multinucleated syncytiotrophoblasts differentiated from 884 
TSCs. c. Detection of CGB in syncytiotrophoblasts differentiated from EPSC-TSCs. 885 
d. RT-qPCR analysis of trophoblast genes in three TSC lines and their derivative 886 
syncytiotrophoblast (ST) and extravillous trophoblast (EVT). e. Detection of HLA 887 
class I by monoclone antibody W6/32 in undifferentiated hESCs, hEPSCs, hTSCs, 888 
and in hEVT differentiated from hTSCs. Compared to hESCs, hEPSCs and hTSCs 889 
expressed substantially lower levels of HLA class I molecules. EVTs are known to 890 
express HLA-C. The choriocarcinoma cells JEG-3 and JAR are representatives of 891 
extravillous and villous trophoblast cells, respectively. JEG-3 express HLA-G and 892 
HLA-C and HLA-E, whereas JAR cells do not express any HLA molecules (Apps, R., 893 
et al. Immunology 2009). They were used as the positive and negative control, 894 
respectively. f. H3K27me3 and H3K4me3 marks at the loci encoding factors 895 
associated with placenta development in pig EPSCEmb and human H1-EPSCs. g. 896 
Images of primary TSC colonies (left) formed from individual pig pEPSCEmb on day 7 897 
cultured in human TSC condition, and of TSCs at passage 7 (right) derived from 898 
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pEPSCEmb. h. Expression of trophoblast factors GATA3 and KRT7 in pEPSCEmb-899 
TSCs detected by immunostaining. Nuclei were stained with DAPI. h. RT-qPCR 900 
analysis of pluripotency and trophoblast stem cells genes in four pEPSCEmb-derived 901 
TSC-like lines and their parental pEPSCEmb. Relative expression levels, normalized to 902 
GAPDH, were compared with those of the parental pEPSCEmb cells. Data are mean ± 903 
s.d. (n = 3). 904 
 905 
Extended Data Figure 12. The effects of inactivation of PARG in human EPSCs on 906 
trophoblast differentiation potential. a. CRISPR/Cas9 mediated deletion of ~350bp in 907 
exon 4 of the PARG gene in the CDX2-H2BVenus reporter hEPSCs. Two gRNAs (g1, 908 
g2) were designed to target the largest coding exon. After transfection and selection, 6 909 
clones out 48 clones were identified as bi-allelic mutants by PCR genotyping and 910 
were confirmed by sequencing. b. The CDX2-reporter EPSC cells with or without the 911 
PARG deletion were treated with the TGFβ inhibitor SB431542 for four days for 912 
trophoblast differentiation. The cells were analysed by flow cytometry. The 913 
percentages of Venus+ cells indicate the extent of trophoblast differentiation of the 914 
parental cells. Inactivation of PARP caused decreased Venus+ cells. Similar results 915 
were obtained in experiments using two independent PARP-deficient hEPSC lines. c-916 
e. RT-qPCR analysis of expression of trophoblast genes in cells differentiated from 917 
either the control (wild type) or the PARG-deficient CDX2-H2BVenus H1-EPSCs, 918 
after 6 days of SB431542 treatment. Significantly lower trophoblast gene expression 919 
was found in the PARG-deficient cells. *p < 0.05. Data are mean ± s.d. (n = 3). 920 
Experiments were repeated at least three times. 921 
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Table 1. Derivation of pEPSCs from preimplantation embryos  
 
 
 
Embryo origins No. of  blastocyst 
No. (%) of 
outgrowth 
No. (%) of  
cell lines 
Parthenogenetic 252 24 (10) 12 (50) 
In vivo derived 76 27 (36) 26 (96.3) 
